Pacira announces data from EXPAREL clinical study presented at ASPS 2011 meeting

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that the company's lead investigational product for postsurgical pain management, EXPAREL™ (bupivacaine liposome extended-release injectable suspension), was highlighted in the "Hot Topics in Plastic Surgery" panel at the annual scientific assembly of the American Society of Plastic Surgeons (ASPS) in Denver, Colo. In addition, new data demonstrating the long-term safety of EXPAREL following augmentation mammoplasty (breast augmentation) using silicone implants were presented during an oral session at ASPS.

Currently under review with the U.S. Food and Drug Administration, EXPAREL is an innovative long-acting bupivacaine that has been shown in multiple Phase 2 and Phase 3 clinical studies to provide prolonged postsurgical analgesia for up to 72 hours with a single-dose local administration at the surgical site. The drug combines bupivacaine with DepoFoam®, a proven product delivery technology that encapsulates medications and delivers them over a desired time period.

Richard A. Baxter, M.D., a practicing plastic surgeon in the Seattle area and former president of the Washington Society of Plastic Surgeons and the Northwest Society of Plastic Surgeons, presented an overview of EXPAREL, including the clinical efficacy data to date, at the "Hot Topics in Plastic Surgery" panel on Friday, September 23, 2011.

"Patient safety, comfort and satisfaction are of primary importance to surgeons and to the success of their practices," said Dr. Baxter. "The thought of postsurgical pain is one of the biggest impediments for patients considering elective operations such as cosmetic plastic surgery. Traditional opioid medications have a long list of drawbacks including nausea, constipation and inconsistent pain relief, so a new therapy like EXPAREL, which blocks the pain at its source for up to three days and potentially reduces the need for opioids, could be a game changer."

Also at ASPS, new data from a two-year observational study of EXPAREL following breast augmentation were presented during an oral session on Saturday, September 24, 2011. The study, a long-term follow-up of 94 subjects enrolled in prior Phase 2 and Phase 3 studies who underwent breast augmentation at multiple sites in the U.S. and received either bupivacaine or EXPAREL, evaluated patients from 13 to 24 months following surgery; new key finding include:

• EXPAREL did not have any impact on normal healing in the presence of silicone breast implant material.
• There was no meaningful difference in impact on breast appearance or implant material in the bupivacaine versus EXPAREL groups.
• Neither EXPAREL nor bupivacaine were associated with any serious adverse events, deaths or withdrawals from the study.

"EXPAREL represents a much needed advance in perioperative, site-specific pain relief therapies, and this study demonstrates the long-term safety profile of EXPAREL following breast augmentation," said Harold Minkowitz, M.D., the study's lead author and a staff anesthesiologist at Memorial Hermann Memorial City Medical Center in Houston, Texas. "After evaluating patients for up to two years after the procedure, we concluded that EXPAREL did not interfere with the patient's healing process or the integrity of the implant material, and was not associated with any late-stage adverse events."

According to the ASPS, breast augmentation has been the most performed cosmetic surgical procedure since 2006. In 2010, approximately 296,000 breast augmentations were performed, 60 percent of which used silicone implants. In the last decade, the number of breast augmentations performed has increased by 39 percent.

"We are pleased to present these data that reinforce the safety and efficacy of EXPAREL to the plastic surgeon community," said Dave Stack, president and chief executive officer of Pacira Pharmaceuticals, Inc. "Based upon our market research, we believe that plastic surgeons will have significant and immediate interest in the use of EXPAREL, should it be approved by the FDA later this year, for breast augmentation and abdominoplasty [tummy tuck] surgeries, a market that includes approximately one million annual procedures. Beyond this initial market opportunity, we believe that EXPAREL can address a significant, unmet medical need to provide long-acting non-opioid postsurgical pain relief in more than 24 million procedures per year in the U.S. alone."